RxDoctor Payments Data

Joseph Longhitano, MD

Cardiovascular Disease · Middletown, CTNPI 1639180938

Payments from drug & device makers

$645in general payments, 2019–2025

Across 41 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$297
  • Novartis$97
  • Amarin Pharma, Inc.$57
  • Pfizer$42
  • Boehringer Ingelheim$35
  • Boston Scientific$31
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$62497%
  • Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$645 in reported general payments places this provider in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$139,608
Medicare patients
1,004
Services billed
1,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban347$443,715
XareltoRivaroxaban90$120,664
JardianceEmpagliflozin52$84,010
Repatha SureclickEvolocumab74$61,046
EntrestoSacubitril/Valsartan34$35,248
MultaqDronedarone Hcl18$26,381
NexletolBempedoic Acid13$10,184
Praluent PenAlirocumab12$8,466
Dabigatran EtexilateDabigatran Etexilate Mesylate13$5,708
Eplerenone50$4,196
Ranolazine ErRanolazine15$3,109
Ezetimibe125$2,503
AtacandCandesartan Cilexetil12$2,115
Metoprolol Succinate124$1,675
Nebivolol Hcl30$1,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$443,715347 claims
Boehringer IngelheimJardiance$35$84,01052 claims
NovartisEntresto$97$35,24834 claims
Sanofi-aventis U.S. LLCMultaq$22$26,38118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →